Clinical Psychopharmacology Unit, Research Department Clinical Educational and Health Psychology, University College London, London, United Kingdom.
Department of Anaesthesia and Perioperative Medicine, University College London Hospital, London, United Kingdom.
Int J Neuropsychopharmacol. 2021 Jul 23;24(7):551-561. doi: 10.1093/ijnp/pyab009.
Nitrous oxide (N2O) is an anesthetic gas with both therapeutic and abuse potential. Because N2O is an NMDA receptor (NMDAR) antagonist, its effects are expected to resemble those of the prototypical NMDAR antagonist, ketamine. In this study, we examined the subjective rewarding effects of N2O using measures previously employed in studies of ketamine. We also tested for moderation of these effects by bipolar phenotype, depressive symptoms, and impulsivity.
Healthy volunteers were randomly assigned to either 50% N2O (n = 40) or medical air (n = 40). Self-reported rewarding (liking and wanting), and alcohol-like effects were assessed pre-, peri- and post inhalation.
Effect sizes for the various rewarding/alcohol-like effects of N2O were generally similar to those reported in studies of moderate-dose ketamine. Impulsivity moderated the subjective reinforcing (liking) effects of inhaled gas, while depressive symptoms moderated motivational (wanting [more]) effects. However, depression and impulsivity had opposite directional influences, such that higher impulsivity was associated with higher N2O liking, and higher depression, with lower N2O wanting.
To the extent that static (versus longitudinal) subjective rewarding effects are a reliable indicator of future problematic drug use, our findings suggests that impulsivity and depression may predispose and protect, respectively, against N2O abuse. Future studies should examine if these moderators are relevant for other NMDAR antagonists, including ketamine, and novel ketamine-like therapeutic and recreational drugs. Similarities between moderate-dose N2O and moderate-dose ketamine in the intensity of certain subjective effects suggest that N2O may, at least to some extent, serve as substitute for ketamine as a safe and easily implemented experimental tool for probing reward-related NMDAR function and dysfunction in humans.
氧化亚氮(N2O)是一种具有治疗作用和滥用潜力的麻醉气体。由于 N2O 是一种 NMDA 受体(NMDAR)拮抗剂,其作用预计与典型的 NMDAR 拮抗剂氯胺酮相似。在这项研究中,我们使用先前研究氯胺酮的方法来检查 N2O 的主观奖赏效应。我们还测试了双相表型、抑郁症状和冲动性对这些效应的调节作用。
健康志愿者被随机分配到 50% N2O(n = 40)或医用空气(n = 40)组。在吸入前、吸入中和吸入后,自我报告的奖赏(喜欢和想要)和酒精样效应。
N2O 的各种奖赏/酒精样效应的效应大小通常与中度剂量氯胺酮研究报告的相似。冲动性调节吸入气体的主观强化(喜欢)效应,而抑郁症状调节动机(想要[更多])效应。然而,抑郁和冲动性具有相反的方向影响,即较高的冲动性与较高的 N2O 喜欢有关,而较高的抑郁与较低的 N2O 想要有关。
在静态(而非纵向)主观奖赏效应是未来有问题药物使用的可靠指标的程度上,我们的发现表明,冲动性和抑郁可能分别易患和保护 N2O 滥用。未来的研究应检查这些调节剂是否与其他 NMDAR 拮抗剂(包括氯胺酮)以及新型氯胺酮样治疗和娱乐性药物相关。中等剂量 N2O 和中等剂量氯胺酮在某些主观效应强度上的相似性表明,N2O 至少在某种程度上可以替代氯胺酮,作为一种安全且易于实施的实验工具,用于在人类中探测与奖赏相关的 NMDAR 功能和功能障碍。